72 results
6-K
EX-99.1
PRFX
PainReform Ltd
15 May 24
Condensed Financial Statements
4:15pm
Operating expenses:
Research and development expenses
General and administrative expenses
Operating loss
Financial income, net
Net loss and comprehensive loss … .
Liquidity
Since its inception, the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising
6-K
EX-99.2
PRFX
PainReform Ltd
15 May 24
Condensed Financial Statements
4:15pm
on our other research and development and commercial development activities. We expect our expenses will increase substantially over time as we … , we may also seek to generate revenue from a combination of research and development payments, license fees and other upfront or milestone payments
6-K
EX-99.3
PRFX
PainReform Ltd
15 May 24
Condensed Financial Statements
4:15pm
for the First Quarter Ended March 31, 2024
Research and development expenses were $4.7 million for the three months ended March 31, 2024, compared to $1.5 … million for the three months ended March 31, 2023, an increase of $3.2 million. The increase in research and development expenses was primarily due
424B4
PRFX
PainReform Ltd
17 Apr 24
Prospectus supplement with pricing info
4:14pm
, the common warrants may not have any value.
Conditions in the Middle East and in Israel may harm our operations.
Our executive office and research … and development facilities are located in Israel. Most of our officers and directors are residents of Israel. Since the establishment of the State of Israel
F-1/A
PRFX
PainReform Ltd
15 Apr 24
Registration statement (foreign) (amended)
9:41am
not have any value.
Conditions in the Middle East and in Israel may harm our operations.
Our executive office and research and development facilities
POS AM
gt4wo
13 Mar 24
Prospectus update (post-effective amendment)
8:00am
F-1
rjfh 7t1k1uh58gxr
1 Mar 24
Registration statement (foreign)
4:34pm
6-K
EX-99.1
zz5 kvfjknsri
1 Mar 24
PainReform Provides Year-End Business Update
8:09am
424B3
qgry ad1a
19 Jan 24
Prospectus supplement
4:30pm
F-3
0qqmkq0ppi7
12 Jan 24
Shelf registration (foreign)
4:15pm
424B3
c4svhho82
27 Dec 23
Prospectus supplement
4:04pm
6-K
kygm1zj e1x46t
27 Dec 23
Inducement Offer to Exercise Warrants Issued in July 2023
4:01pm
6-K
EX-99.1
7e5soq18 cy09
26 Dec 23
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross
6:08pm
6-K
EX-99.3
j3ucc sj9
15 Nov 23
Condensed Financial Statements
4:09pm
6-K
EX-99.2
4ugpt9i
15 Nov 23
Condensed Financial Statements
4:09pm
6-K
EX-99.1
w8kse3
15 Nov 23
Condensed Financial Statements
4:09pm
6-K
EX-99.2
1rr9w0p
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.1
n0uomrduypeox
10 Aug 23
Current report (foreign)
4:18pm
6-K
EX-99.3
sqlm2ftsdw48dtah04
10 Aug 23
Current report (foreign)
4:18pm